Placeholder Banner

BIO Premieres New Ad Highlighting the Value of Biomedical Innovation

February 8, 2016

Washington, D.C. (February 8, 2016) – The Biotechnology Innovation Organization (BIO) today launched a new ad focused on the value of biomedical innovation, highlighting the most compelling benefits of biomedical research – giving patients time to live fuller lives. The ad serves as a cornerstone for BIO’s new Value Campaign, which will provide an avenue for the biotechnology sector to highlight the value of biomedical innovation and includes a new “Time Is Precious” website.

“With this effort, BIO is advancing the national public policy debate over the cost and value of medicine, shining a spotlight on the fact that innovative, life-saving medicines provide benefits far beyond their costs,” said BIO President & CEO Jim Greenwood. “It’s time for the public to hear the voices of those who are benefitting from medical breakthroughs and those who are bringing these breakthroughs to market.”

Through the campaign, the public will see that today’s innovative life-enhancing medicines save and extend lives, improve quality of life and drive value to patients and the healthcare system as a whole. The ad represents just the beginning of BIO’s campaign, which includes a new “Time Is Precious” website.

“Thanks to biomedical breakthroughs we have seen HIV/AIDS death rates drop by 85% since 1995; heart disease death rates have decreased by 30% between 2001 and 2011, and cancer death rates are down 22% since 1991. America’s innovative biopharmaceutical companies are tackling some of our most unrelenting scientific challenges head-on and are delivering new, high-value cures and treatments that are saving and extending the lives of patients and giving them precious time to lead fuller lives,” said Greenwood.

The Value of Medicine advertisement can be viewed HERE.For more information on the advertisement or BIO’s Value Campaign, please visit: http://timeisprecious.life

###

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…